Filing Flows › Humacyte (HUMA) › Q4 2025
Humacyte (HUMA) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 27, 2026
Humacyte (HUMA) reported revenue of $467K for the fourth quarter 2025 (Q4 2025) and -38% from the quarter before.
Humacyte, Q4 2025: revenue $467K, net loss $24.8M, operating cash flow −$26.1M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $467K | -38% | — |
| Operating profit | −$30.8M | — | — |
| Net earnings | −$24.8M | — | — |
| Operating cash flow | −$26.1M | — | — |
What changed
Revenue was $467K in Q4 2025, down 38% from the previous quarter.
Operating costs exceeded revenue by $30.8M, an operating margin of -6603.0%. The quarter ended with a net loss of $24.8M, wider than the previous quarter's $17.5M loss. Non-operating items added $6.0M, -24% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$26.1M. Non-cash charges added back $1.3M of depreciation and $2.5M of share-based compensation. Working capital and other items used $5.1M. Capital expenditures of $39K exceeded it, leaving free cash flow of −$26.2M.
Questions
What was Humacyte's revenue in the fourth quarter 2025?
Humacyte (HUMA) reported revenue of $467K for the fourth quarter 2025 (Q4 2025) and -38% from the quarter before.
Source: Humacyte 10-K on SEC EDGAR.